Wall Street analyst estimates for Immunovant, Inc. (IMVT): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2027E | $6.6M | $6.6M – $6.6M | -$2.94 | 9 |
| 2028E | $42.9M | $42.9M – $42.9M | -$2.92 | 8 |
| 2029E | $403M | $385M – $422M | -$1.87 | 11 |
Fiscal year ending in March · figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 18 |
| Hold | 4 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 23 |
| Avg rating (−2 sell to +2 buy) | 0.74 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.74 | ||
| 2026-08-06 | $-0.75 | $-0.63 | -19.3% |
| 2026-05-20 | $-0.73 | $-0.59 | -23.3% |
| 2026-02-06 | $-0.61 | $-0.72 | +15.3% |
| 2025-11-10 | $-0.73 | $-0.72 | -1.4% |
| 2025-08-11 | $-0.60 | $-0.69 | +13.0% |
| 2025-05-29 | $-0.64 | $-0.71 | +10.3% |
| 2025-02-06 | $-0.76 | $-0.73 | -4.1% |
Valuation Ratios
| Price / Book | 7.94 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $21,000 | 0 | 0 | 0 | 0 | 0 | $409,000 |
| Gross Profit | 0 | 0 | -$21,000 | 0 | 0 | 0 | 0 | 0 | -$409,000 |
| Research & Development | $135.3M | $25.7M | $47.9M | $68.6M | $101.8M | $160.3M | $212.9M | $360.9M | $456.7M |
| Selling, General & Admin | $1.5M | $448 | $11.7M | $39.5M | $54.2M | $48.0M | $57.3M | $77.2M | $76.2M |
| Operating Expenses | $136.7M | $448 | $59.7M | $108.1M | $156.0M | $208.3M | $270.2M | $438.2M | $532.9M |
| Operating Income | -$136.7M | -$450 | -$59.7M | -$108.1M | -$156.0M | -$208.3M | -$270.2M | -$438.2M | -$532.9M |
| EBITDA | 0 | $9,552 | -$65.6M | -$108.1M | -$156.7M | -$198.3M | -$258.5M | -$412.6M | -$505.0M |
| Interest Expense | 0 | 0 | $625,000 | 0 | 0 | $12.5M | 0 | 0 | 0 |
| Pre-tax Income | -$136.7M | -$448 | -$66.3M | -$107.8M | -$156.8M | -$211.0M | -$258.8M | -$412.9M | -$505.4M |
| Income Tax | 0 | 0 | $97,000 | -$358,000 | -$84,000 | $9,000 | $567,000 | $891,000 | $215,000 |
| Net Income | -$136.7M | -$448 | -$66.4M | -$107.4M | -$156.7M | -$211.0M | -$259.3M | -$413.8M | -$505.6M |
| EPS | -$13.68 | -$0.00 | -$1.54 | -$1.22 | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
| EPS (Diluted) | -$13.67 | -$0.00 | -$1.54 | -$1.22 | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
| Shares Outstanding (Diluted) | 10.0 M | 14.4 M | 43.2 M | 87.8 M | 109.7 M | 123.1 M | 138.1 M | 151.6 M | 182.4 M |
Price
| Price | $28.41 (closing price, November 2, 2026) |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: TGTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMVT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks